Ronald L. Merriman
Pfizer (United States)(US)
Publications by Year
Research Areas
Synthesis and biological activity, Melanoma and MAPK Pathways, Prostate Cancer Treatment and Research, Cancer, Hypoxia, and Metabolism, PI3K/AKT/mTOR signaling in cancer
Most-Cited Works
- → Inhibition of protein kinase C by calphostin C is light-dependent(1991)369 cited
- → NCM460, a normal human colon mucosal epithelial cell line(1996)231 cited
- Reversible inhibition by retinoids of 3-methylcholanthrene-induced neoplastic transformation in C3H/10T1/2 clone 8 cells.(1979)
- In vitro and in vivo antitumor activity of the phosphatidylinositol-3-kinase inhibitor, wortmannin.(1995)
- → Comparison of the antitumor activity of gemcitabine and ara-C in a panel of human breast, colon, lung and pancreatic xenograft models(1996)80 cited
- → 2-Alkylamino- and alkoxy-substituted 2-amino-1,3,4-oxadiazoles—O-Alkyl benzohydroxamate esters replacements retain the desired inhibition and selectivity against MEK (MAP ERK kinase)(2008)67 cited
- Modulation of histone acetylation by [4-(acetylamino)-N-(2-amino-phenyl) benzamide] in HCT-8 colon carcinoma.(2003)
- → Evaluation of new anticancer agents against the MIA PaCa-2 and PANC-1 human pancreatic carcinoma xenografts.(1993)63 cited
- → Synthesis and Evaluation of Hydroxylated Polyamine Analogues as Antiproliferatives(1999)52 cited
- → 4-Anilino-5-carboxamido-2-pyridone Derivatives as Noncompetitive Inhibitors of Mitogen-Activated Protein Kinase Kinase(2007)48 cited